EURORDIS website
⌛️ 3h
Start learning now with our free online courses
Our online courses have been developed with subject-area specialists, such as researchers and patient experts, and are regularly updated for the best learning experience and the latest information on all topic areas.
Click below on your topic areas of interest to see the related online courses, links to more information and additional related resources.
Research leads to a better understanding of rare diseases, quicker and more accurate diagnosis, innovative treatments and cures, and better health care. It represents hope for the 30 million people living with a rare disease in Europe and their families.
More information is on the EURORDIS website.
Free
Fundamentals of statistics in clinical trials
Free
Registries: how can you work with existing registries or set up a registry?
⌛️ 1h30m
Free
Introduction to the European and international research landscape
⌛️2h
Free
Genome editing
⌛️ 4h30m
Free
From research to therapies
⌛️3h
Free
Setting the landscape
⌛️ 4h15m
Free
Medicines Research and Development
⌛️ 2h30m
A diagnosis can serve as the key to unlocking access to appropriate medical and social care. Getting an accurate diagnosis even when there is no treatment provides the opportunity for people living with a rare disease and their families to plan their care and future.
More information is on the EURORDIS website.
Free
Introduction to genetics and genomics
⌛️ 2h
Free
Genetic research to clinical diagnosis of Rare Diseases
⌛️ 3h45m
Once a child or adult is diagnosed with a rare disease, their next logical step is to search for a treatment.
Treatments provide relief to people living with a rare disease and their families. A treatment can slow down the progression of a disease, treat the symptoms or cure the disease. They ease the reality of living with a rare disease every day.
More information is on the EURORDIS website.
Free
Ethics in clinical trials
⌛️ 2h
Free
The European Medicines Agency (EMA)
⌛️ 1h30
Free
Market access & Health Technology Assessment
⌛️ 1h30
Free
Benefit-risk assessment and pharmacovigilance
⌛️ 2h 45m
Free
Medicines Regulatory Framework and Procedures
⌛️ 2h
Advocacy contributes to bringing about impactful change for people living with a rare disease by ensuring national, European and international policies are created and developed taking into account the needs of our community – 30 million people living with a rare disease in Europe, 300 million people around the world, plus their families, carers and healthcare providers.
More information is on the EURORDIS website.
Free
Survey design for rare disease patient organisations
⌛️ 5h
Free
Establishing an international cooperation
⌛️ 2h30m
Free
International advocacy for rare diseases
⌛️ 2h30m
Free
Ordinary Legislative Procedure – How are decisions taken by the EU?
⌛️ 1h30
Free
Introduction to the European Union Institutions
⌛️ 2h
Sharing health data to advance scientific research and improve clinical practice is of particular importance to the 30 million people living with a rare disease in Europe, where knowledge and expertise are limited, patient populations are geographically dispersed, and health data is scattered.
Free
Sharing patient data
⌛️ 4h30m
Patient engagement is defined as the desire and capability to actively choose to participate in care in a way uniquely appropriate to the individual, in cooperation with a healthcare provider or institution, for the purposes of maximizing outcomes or improving experiences of care.
Free
Recommendations on the required capabilities for patient engagement
⌛️ 2h
Free
Conflict of interest in patient engagement
⌛️ 2h
More information is on the EURORDIS website:
Free
Creating Great Mobile Video
⌛️ 2h30m
Free
Plan & Create for Social Media Success
⌛️ 1h
Free
Reaching the Right People: Celebrities and Influencers
⌛️ 1h15m
Free
The Power of Community
⌛️ 2h30m
The Open Academy eLearning is funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HaDEA. Neither the European Union nor the granting authority can be held responsible for them.
